Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 17, Issue 1, Pages 119-128
Publisher
Informa UK Limited
Online
2016-11-22
DOI
10.1080/14712598.2017.1263614
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis
- (2017) Tetsuo Hasegawa et al. JOINT BONE SPINE
- Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study
- (2017) Jiang Yue et al. ARTHRITIS CARE & RESEARCH
- Response to: ‘Denosumab, cortical bone and bone erosion in rheumatoid arthritis’ by Rossiniet al
- (2016) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Denosumab, cortical bone and bone erosions in rheumatoid arthritis
- (2016) Maurizio Rossini et al. ANNALS OF THE RHEUMATIC DISEASES
- Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
- (2016) Georg Schett et al. ANNALS OF THE RHEUMATIC DISEASES
- Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis
- (2016) Giovanni Adami et al. CALCIFIED TISSUE INTERNATIONAL
- Unknown
- (2016) JOURNAL OF BONE AND MINERAL RESEARCH
- Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience
- (2016) Beatrice J Edwards et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis
- (2016) Hayato Kinoshita et al. Modern Rheumatology
- Closing the loop on the bone-resorbing osteoclast
- (2016) Mone Zaidi et al. NATURE MEDICINE
- LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption
- (2016) Jian Luo et al. NATURE MEDICINE
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
- (2016) Glen S Hazlewood et al. BMJ-British Medical Journal
- Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws
- (2016) Sarina E.C. Pichardo et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
- (2016) Glen S Hazlewood et al. BMJ-British Medical Journal
- Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis
- (2016) Nida Meednu et al. Arthritis & Rheumatology
- Molecular regulatory mechanisms of osteoclastogenesis through cytoprotective enzymes
- (2016) Hiroyuki Kanzaki et al. Redox Biology
- Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis
- (2016) Prakirthi Yerram et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects
- (2015) Yun Xue et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review
- (2015) Demba Diédhiou et al. ANNALES D ENDOCRINOLOGIE
- Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients withRheumatoId arthritis on methotrexate toValidate inhibitory effect on boneErosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Hypocalcaemia in patients with metastatic bone disease treated with denosumab
- (2015) Jean-Jacques Body et al. EUROPEAN JOURNAL OF CANCER
- RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects
- (2015) C. Di Nisio et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway
- (2015) Chang-hong Li et al. INFLAMMATION RESEARCH
- Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys
- (2015) Paul J Kostenuik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial
- (2015) Bente L. Langdahl et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Elevated incidence of fractures in women with invasive breast cancer
- (2015) B. J. Edwards et al. OSTEOPOROSIS INTERNATIONAL
- The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
- (2015) S. Papapoulos et al. OSTEOPOROSIS INTERNATIONAL
- Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics
- (2015) A. W. Popp et al. OSTEOPOROSIS INTERNATIONAL
- Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review
- (2015) J. Selga et al. OSTEOPOROSIS INTERNATIONAL
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- (2015) Alison T. Stopeck et al. SUPPORTIVE CARE IN CANCER
- Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
- (2015) Aase Haj Hensvold et al. ARTHRITIS RESEARCH & THERAPY
- Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab
- (2015) Jeffrey R. Curtis et al. Arthritis & Rheumatology
- Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
- (2015) Ove Törring Therapeutic Advances in Musculoskeletal Disease
- Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis
- (2014) L Yeo et al. ANNALS OF THE RHEUMATIC DISEASES
- Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases
- (2014) M O'Halloran et al. AUSTRALIAN DENTAL JOURNAL
- Patients with Rheumatoid Arthritis in Clinical Remission Manifest Persistent Joint Inflammation on Histology and Imaging Studies
- (2014) A. Anandarajah et al. JOURNAL OF RHEUMATOLOGY
- Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
- (2014) XIN WANG et al. Oncology Letters
- Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
- (2014) Matthew C. Walsh et al. Frontiers in Immunology
- Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies
- (2013) Arnd Kleyer et al. ANNALS OF THE RHEUMATIC DISEASES
- Identification of the Risk Factors Associated with Hypocalcemia Induced by Denosumab
- (2013) Naoto Okada et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Involvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis
- (2013) Maurizio Rossini et al. CALCIFIED TISSUE INTERNATIONAL
- Dynamic visualization of RANKL and Th17-mediated osteoclast function
- (2013) Junichi Kikuta et al. JOURNAL OF CLINICAL INVESTIGATION
- The role of the serum RANKL/OPG ratio in the healing of intertrochanteric fractures in elderly patients
- (2013) XUE-FEI WANG et al. Molecular Medicine Reports
- Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis
- (2013) Noriko Komatsu et al. NATURE MEDICINE
- Pain outcomes in patients with advanced breast cancer and bone metastases
- (2012) Charles S. Cleeland et al. CANCER
- Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
- (2012) M. Martin et al. CLINICAL CANCER RESEARCH
- Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude
- (2012) Marcus Zulian Teixeira Homeopathy
- Receptor Activator of Nuclear Factor κB Ligand (RANKL) Protein Expression by B Lymphocytes Contributes to Ovariectomy-induced Bone Loss
- (2012) Melda Onal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing
- (2012) Silvano Adami et al. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
- (2012) Davide Gatti et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab in patients with cancer—a surgical strike against the osteoclast
- (2012) Janet E. Brown et al. Nature Reviews Clinical Oncology
- Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
- (2012) Georg Schett et al. Nature Reviews Rheumatology
- The relationship of denosumab pharmacology and osteonecrosis of the jaws
- (2012) John Malan et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
- (2011) Ya-Hui Chiu et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
- (2011) D. Castellano et al. ONCOLOGIST
- The RANKL Pathway and Denosumab
- (2011) Robin K. Dore RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Denosumab and bisphosphonates: Different mechanisms of action and effects
- (2010) Roland Baron et al. BONE
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab-related osteonecrosis of the jaws
- (2010) A. Kyrgidis et al. OSTEOPOROSIS INTERNATIONAL
- Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
- (2010) Anna Wasilewska et al. PEDIATRIC NEPHROLOGY
- Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
- (2010) John T. Sharp et al. ARTHRITIS CARE & RESEARCH
- Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients
- (2010) A. Deodhar et al. ARTHRITIS CARE & RESEARCH
- Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice
- (2009) Susann Helas et al. AMERICAN JOURNAL OF PATHOLOGY
- Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
- (2009) R. K. Dore et al. ANNALS OF THE RHEUMATIC DISEASES
- RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4–Dependent Pathway
- (2009) Sara Panizo et al. CIRCULATION RESEARCH
- Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation
- (2009) Takako Negishi-Koga et al. IMMUNOLOGICAL REVIEWS
- Osteoimmunology: Crosstalk Between the Immune and Bone Systems
- (2009) Tomoki Nakashima et al. JOURNAL OF CLINICAL IMMUNOLOGY
- RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4 + CD25 + Regulatory T Cells in Chronic Colitis
- (2009) Teruji Totsuka et al. JOURNAL OF IMMUNOLOGY
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure
- (2008) U M. Dohn et al. ANNALS OF THE RHEUMATIC DISEASES
- Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
- (2008) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis
- (2008) Agnès Ostertag et al. BONE
- Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
- (2008) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started